# Safety of Single Rising Doses and Relative Bioavailability of BI 691751

> **NCT01843972** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 81 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 691751
- **DRUG:** BI 691751
- **DRUG:** Placebo
- **DRUG:** BI 691751
- **DRUG:** BI 691751
- **DRUG:** BI 691751
- **DRUG:** BI 691751
- **DRUG:** BI 691751
- **DRUG:** BI 691751
- **DRUG:** BI 691751

## Key facts

- **NCT ID:** NCT01843972
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2016-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01843972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01843972, "Safety of Single Rising Doses and Relative Bioavailability of BI 691751". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01843972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*